CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 39 enrolled
Drug / intervention
Isoflavone +1 moredrug
Likely dose
Not stated in record
Key inclusion· 3
  • ✓Age 21 years or older
  • ✓Diagnosis of prostate cancer
  • ✓Androgen deprivation therapy-induced hypogonadism for at least 3 months
Key exclusion· 3
  • ✕Current use of growth-promoting agents
  • ✕Current use of appetite-stimulating agents
  • ✕Current use of Prednisone or other corticosteroids

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00245518
NCT00245518Phase 4Completed
CompareCT.gov

Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Johns Hopkins University·interventional·Posted Oct 28, 2005·Updated Oct 13, 2017

In Brief

A Phase 4 clinical trial evaluating Isoflavone and Placebos for Hot Flashes. Completed, enrolled 39 participants across 1 site.

Detailed Summary

This study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy. Hypothesis: Treating men who have prostate CA with daily Revival will result in at least a 50% reduction in hot flashes compared to placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHot Flashes
CountriesUnited States
CollaboratorsPhysicians Laboratories, National Cancer Institute (NCI)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 2005
Enrollment StartJun 1, 2005
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.7 years ago

Interventions

Isoflavonedrug

Placebosdrug